AV网在线不卡免费看|AV最新网址在线免费|a在线免费观看网站|yy6080亚洲人久久精品

擅長領(lǐng)域：肺癌、鼻咽癌和大腸癌等常見腫瘤的內(nèi)科治療和多學(xué)科綜合治療，同時對晚期癌癥病人的對癥支持治療如：癌性貧血的治療、惡性腫瘤骨轉(zhuǎn)移的治療、化療導(dǎo)致的惡心嘔吐治療、晚期病人的疼痛的治療。?

執(zhí)業(yè)經(jīng)歷： 　　1963年3月出生，河南洛陽人。中共黨員。教授、主任醫(yī)師、腫瘤內(nèi)科博士生導(dǎo)師。1986年畢業(yè)于中山醫(yī)科大學(xué)臨床醫(yī)學(xué)系，獲得學(xué)士學(xué)位。1991年中山醫(yī)科大學(xué)臨床腫瘤學(xué)碩士畢業(yè)，獲得碩士學(xué)位。先后赴法國巴黎Institut Gustave Roussy腫瘤中心、美國Fox Chase腫瘤中心、美國M.D.Anderson腫瘤中心進(jìn)修。現(xiàn)任中山大學(xué)附屬腫瘤醫(yī)院內(nèi)科副主任，中山大學(xué)肺癌研究中心副主任，中山大學(xué)附屬腫瘤醫(yī)院國家新藥(抗腫瘤藥物)臨床研究(GCP)中心主任、I期病房主任，國家藥品食品監(jiān)督管理局(SFDA)藥物評審咨詢專家、澳門鏡湖醫(yī)院放射治療中心顧問醫(yī)生。并先后任中國抗癌協(xié)會腫瘤康復(fù)與姑息治療專業(yè)委員會副主任委員、化療專業(yè)委員、肺癌專業(yè)委員會委員;廣東省抗癌協(xié)會腫瘤康復(fù)與姑息治療專業(yè)委員會主任委員，廣東省抗癌協(xié)會化療專業(yè)委員會、肺癌專業(yè)委員會副主任委員等職位。主要研究方向：肺癌和鼻咽癌等實體瘤的化學(xué)治療、靶向治療、多學(xué)科綜合治療以及晚期癌癥的姑息治療。發(fā)表SCI論文40余篇，國內(nèi)核心期刊論文70余篇。主編及參與編寫腫瘤專業(yè)的專著9本。榮獲廣東省科學(xué)技術(shù)研究成果三等獎(第一完成人)和廣東醫(yī)藥衛(wèi)生科技進(jìn)步獎三等獎(第四完成人)。 　　海外留學(xué)經(jīng)歷： 　　1996年赴法國巴黎Institut Gustave Roussy(IGR)腫瘤中心短期進(jìn)修。 　　1998年赴美國費城Fox Chase腫瘤中心短期進(jìn)修。 　　2001-2002年在美國德州大學(xué)M.D.Anderson腫瘤中心進(jìn)修。 　　臨床醫(yī)療經(jīng)驗： 　　自1986年一直在中山醫(yī)科大學(xué)腫瘤防治中心從事腫瘤化療醫(yī)療、教學(xué)和科研工作及抗癌藥物的臨床研究，擅長肺癌、鼻咽癌和大腸癌等實體瘤的化學(xué)治療、靶向治療、多學(xué)科綜合治療。同時對晚期癌癥病人的對癥支持治療如：癌性貧血的治療、惡性腫瘤骨轉(zhuǎn)移的治療、化療導(dǎo)致的惡心嘔吐治療、晚期病人的疼痛的治療等方面也有較深入的研究。負(fù)責(zé)執(zhí)筆撰寫中國版《NCCN非小細(xì)胞肺癌臨床指導(dǎo)原則》、《雙磷酸鹽治療肺癌骨轉(zhuǎn)移的專家共識》及《腫瘤相關(guān)貧血治療專家共識》等多個臨床共識，參與撰寫《NCCN結(jié)腸/直腸癌臨床指導(dǎo)原則》、《NCCN頭頸癌臨床指導(dǎo)原則》、《表皮生長因子受體抑制劑導(dǎo)致皮疹治療的專家共識》。在國內(nèi)最早開展和應(yīng)用放療前的誘導(dǎo)化療治療局部晚期鼻咽癌和大劑量醛氫葉酸+5FU持續(xù)滴注48小時(雙周療法)治療晚期大腸癌的臨床研究、非鉑類方案治療晚期非小細(xì)胞肺癌、分子靶向用于非小細(xì)胞肺癌的維持治療的臨床研究。在國內(nèi)首創(chuàng)癌痛規(guī)范化治療示范病房(GPM)項目，并將該項目成功向全國推廣。目前擔(dān)任衛(wèi)生部合理用藥專家委員會抗腫瘤藥專業(yè)組成員、衛(wèi)生部癌痛規(guī)范化治療專家組副組長、廣東省干部保健專家、廣州市干部保健專家。 　　科學(xué)研究經(jīng)驗： 　　對抗癌新藥臨床研究的程序、原則、組織和實施有非常豐富的實際操作經(jīng)驗，主持或作為主要參與者的藥物臨床研究包括：卡鉑、長春瑞濱、多西紫杉醇、草酸鉑、馬藺子素膠囊、rhG-CSF、帕米磷酸二鈉、拓?fù)涮婵怠⒓翘婺?、厄洛替尼、?？颂婺?、阿帕替尼、法米替尼、昔妥西單抗、貝伐單抗、培美曲賽、S-1、血管內(nèi)皮抑素等。直接參與一些國家創(chuàng)新(I類新藥)藥物(如：有機(jī)鍺、腫瘤壞死因子、基因工程溶瘤腺病毒H101、基因工程腺病毒-TK基因治療、?？颂婺帷⑴撂婺?、法米替尼、長效血管內(nèi)皮抑素、氟拉哌索、Aflibercept)的藥代動力學(xué)研究和臨床試驗觀察工作。主持(PI)國際多中心臨床研究一項、國家級多中心臨床研究十多項，參與30多項國際多中心臨床研究、擔(dān)任多個國際多中心研究的獨立數(shù)據(jù)管理委員會(IDMC)成員和專家委員會(SC)成員。受國家藥品食品監(jiān)督管理局(SFDA)委托負(fù)責(zé)起草《抗腫瘤藥物臨床研究技術(shù)指導(dǎo)原則》(2006年，第二版)。近年來分別承擔(dān)和參與了多項國家級科技攻關(guān)的科研基金(包括九五、十一五、1035計劃項目、863項目、973項目、新藥創(chuàng)制國家重大專項)、廣東省自然科學(xué)基金、廣東省重點科技攻關(guān)基金、廣東省醫(yī)學(xué)科研基金、廣州市科技局基金等研究。參與中山大學(xué)附屬腫瘤醫(yī)院國家級抗癌藥物臨床試驗研究中心的論證、籌建工作。成功組織和籌備每年度的廣東省抗癌協(xié)會化療專業(yè)委員會會議，以及國家級繼續(xù)教育項目GCP培訓(xùn)班等。在SCI雜志發(fā)表論文40篇，其中包括第一作者或通訊作者的文章如：《Lancet Oncology》(SCI=22.589，第一及通訊作者)、《Journal of Clinical Oncology》(SCI=11.81，第一及通訊作者)、《Annals Oncology》(SCI=6.425，通訊作者)《European Journal of Cancer》(SCI=4.47通訊作者)、《Journal of Thoracic Cancer》(SCI=4.5通訊作者)、《Lung Cancer》(SCI=3.46，第一作者)、《Cancer Gene Therapy》(SCI=3.89，通訊作者)、《Cancer Chemotherapy and Pharmacology》(SCI=2.2，第一作者)等22篇，作為作者之一的文章如：《Journal of Clinical Oncology》(SCI=17.3)、《Lancet Oncology》(SCI=13.28)、《Cancer》(SCI=4.8)、《Journal of Thoracic Oncology》(SCI=3.5)、《Oncology》(SCI=1.9)、《Clinical Lung Cancer》等文章18篇。在國內(nèi)核心期刊發(fā)表論文90余篇。主編及參與編寫腫瘤專業(yè)的專著有9本。獲廣東省科學(xué)技術(shù)研究成果三等獎(第一完成人)、廣東醫(yī)藥衛(wèi)生科技進(jìn)步獎三等獎(第四完成人)各一次。 　　教學(xué)工作經(jīng)驗： 　　自1986年至今一直在中山醫(yī)科大學(xué)腫瘤防治中心內(nèi)科從事腫瘤化療本科生和進(jìn)修醫(yī)生的臨床教學(xué)工作，擔(dān)任本科生臨床見習(xí)帶教兩次、1995年兼任本科生兼職班主任一次(一年)、一年制進(jìn)修醫(yī)生班主任一次。從1997年擔(dān)任內(nèi)科副主任后一直分管教學(xué)工作至2008年。1998年開始招收臨床型碩士研究生，現(xiàn)共培養(yǎng)臨床型碩士生12名、科研型碩士2名、七年制碩士3名、留學(xué)生1名。2009年開始招收博士研究生5名。獲中山醫(yī)科大學(xué)青年教師講課比賽三等獎一次。 　　科研獲獎項目： 　　1.《5-氟尿嘧啶/醛氫葉酸雙周療法治療惡性腫瘤》 廣東省科學(xué)技術(shù)研究成果三等獎，2006年度，排名第一 　　2.《晚期鼻咽癌化學(xué)治療的研究》 廣東省醫(yī)藥衛(wèi)生科技進(jìn)步獎三等獎，1998年度，排名第四 　　科研基金： 　　2002年以前獲得獲得科研基金： 　　1.廣東省醫(yī)學(xué)科研基金：重組腺病毒的藥代動力學(xué)及毒理學(xué)研究(A2001042)(2001-2003年)李蘇、張力、王安訓(xùn)、廖海、何友兼 　　2.廣東省醫(yī)學(xué)科研基金：5-FU靶酶及其代謝酶生物多態(tài)性與結(jié)直腸癌化療療效之相關(guān)性的研究(A2001222)(2001-2003年)張力、潘志忠、陳功、錢曉洲、夏忠軍、李蘇、廖海 　　3.國家高技術(shù)研究發(fā)展計劃(“863”計劃)：H101基因工程腺病毒的中試研究(分題)(102-1202-06)(2000-2002年)張力、徐瑞華、夏忠軍、廖海、李蘇 　　4.國家醫(yī)藥技術(shù)創(chuàng)新項目：篩選逆轉(zhuǎn)腫瘤細(xì)胞對順氯氨鉑(DDP)的抗藥性逆轉(zhuǎn)劑(96-901-06-73)(2000-2001年)徐瑞華、符立梧、廖海、姜文奇、李蘇、梁永鉅、管忠震、張力 　　5.廣州市科技計劃項目：粉防己堿臨床逆轉(zhuǎn)乳癌、骨肉瘤多藥抗藥性的研究(2000-Z-110-08)(2000-2003年)楊小平、姜文奇、沈靖南、符立梧、梁永鉅、張力、李蘇、王晉、蘇秀容、湯昊 　　6.廣東省百項工程項目：新藥臨床試驗研究中心(GCP)(99B07902Q)(1999-2002年)姜文奇、張力、徐瑞華、劉冬耕、黃民、徐光川、黃慧強(qiáng)、譚悅、廖海、周中梅 　　7.廣東省重點科技攻關(guān)項目：粉防已堿臨床逆轉(zhuǎn)腫瘤多藥抗藥性研究(99M04401G)(1999-2002年)符立梧、姜文奇、楊安奎、周晏、徐瑞華、張力、梁永鉅、潘啟超 　　8.廣東省重點科技攻關(guān)項目：惡性淋巴瘤臨床特征與細(xì)胞周期調(diào)節(jié)蛋白及基因變異關(guān)系的研究(99M04911G)(1999-2002年)徐瑞華、姜文奇、邵建永、張力、孫曉非、周中梅、侯景輝、管忠震 　　9.廣東省醫(yī)藥科研基金：彌漫性大B細(xì)胞淋巴瘤預(yù)后與細(xì)胞周期調(diào)控蛋白的關(guān)系(A1999208)(1999-2001年)徐瑞華、姜文奇、邵建永、周中梅、張力、喻慶薇、侯景輝 　　2002年 　　1.國家高技術(shù)研究發(fā)展計劃(863計劃)：臨床試驗關(guān)鍵技術(shù)及平臺研究(2002AA2Z34IC)姜文奇、管忠震、張力、徐瑞華、夏忠軍、蘇蘇、黃民、劉冬耕、孫曉非、黃慧強(qiáng)、李志銘、李建紅、曹燁、郭穎 　　2.廣東省醫(yī)學(xué)科研基金：I-III期非小細(xì)胞肺癌現(xiàn)代治療的新策略和多學(xué)科協(xié)作模式的建立(A2002229)王欣、張力、戎鐵華、盧泰祥、陳明、吳秋良、馬剛、林鵬、楊學(xué)寧、黃培鈺 　　2004年 　　1.廣東省科技計劃項目：組織微陣列方法分析NSCLC含鉑方案化療敏感性相關(guān)性研究(2004B30301006)張力、張陽、徐菲、李寧、李蘇、張星、廖海、汪波、侯景輝、郭穎 　　2.廣東省科技計劃項目：N2期非小細(xì)胞肺癌新輔助治療策略的臨床研究(2004B30301008)王欣、戎鐵華、張力、陳明、鄭列、張惠忠、馬剛、王旭東、王春梅、王軍業(yè) 　　2005年 　　1.“985工程”二期建設(shè)項目：酪氨酸激酶抑制劑在鼻咽癌中應(yīng)用的臨床與實驗研究。張力、黃培鈺、李蘇、張星、廖海、汪波、侯景輝 　　2006年 　　1.廣東省科技計劃項目：以分子標(biāo)記物預(yù)測和預(yù)防非小細(xì)胞肺癌骨轉(zhuǎn)移的基礎(chǔ)和臨床研究 (2006B36002004)張力、王欣、汪波、云徑平、侯景輝、侯雪、林麗珊 　　2.“十一五”國家科技支撐計劃：常見惡性腫瘤預(yù)防、早診及綜合治療研究項目非小細(xì)胞肺癌規(guī)范化多學(xué)科綜合治療的多中心協(xié)作研究(課題2)(主要參加人員) 　　2007年 　　1.廣東省自然科學(xué)基金：EGFR-TKI治療肺癌的基因組學(xué)及蛋白質(zhì)組學(xué)研究(07001532)張力、王欣、李蘇、廖海、黃河、張陽、趙洪云、田瑩、林立平、吳烜 　　2.國家高技術(shù)研究發(fā)展計劃(863計劃)課題：鼻咽癌的分子分型和個體化診療(2006AA02A404)(molecular classification, personalized diagnosis and therapy of nasopharyngeal carcinoma.)子課題：鼻咽癌個體化化療和分子靶向治療的探索。張力、李宇紅、麥海強(qiáng)、曹素梅、黃培玉、洪明晃、郭翔 　　2008年 　　1. 新藥創(chuàng)制國家重大專項：臨床試驗評價技術(shù)平臺(2008ZX09312-002)(Major science and technology project of "National Significant new drug creation")。子課題：新型靶向藥物臨床研究的探索 　　2. 新藥創(chuàng)制國家重大專項：?？颂婺嶙诱n題(2008ZX09101-11)：?？颂婺嶂委熗砥诜切〖?xì)胞肺癌的II/III期臨床研究。張力、史艷俠、陳麗昆、黃巖 　　2009年 　　1.吳階平醫(yī)學(xué)基金會(08-JC-003)：比較500mg吉非替尼與250mg吉非替尼用于經(jīng)吉非替尼治療1月后疾病穩(wěn)定的晚期非小細(xì)胞肺癌患者的隨機(jī)II期臨床研究(2009-2011)張力、鄧燕明、張為民、賈筠、董維(250萬) 　　2010年 　　1. CSCO血管靶向治療基金：腫瘤內(nèi)微血管密度(MVD)預(yù)測貝伐單抗(Bev)聯(lián)合化療的療效的研究。(2010-2012)張力、陳麗昆、黃巖、梁穎(20萬) 　　2. 廣州市科技計劃項目：FCγR基因多態(tài)性預(yù)測愛必妥治療NSCLC療效價值的臨床研究。(2010-2012)張力、史艷俠、陳麗昆、黃巖、田瑩、趙媛媛、蔣瑋、薛聰(15萬) 　　2011年 　　1. 廣東省衛(wèi)生廳基金(A2011203)：miR7與EGFR-TKI用藥療效相關(guān)性的實驗研究。(2010-2012)黃巖、趙洪云、田瑩、趙媛媛、薛聰、王樹森、張力(2萬) 　　2. 勃林格殷格翰：BIBF1120治療鼻咽癌的臨床前研究 　　3. 勃林格殷格翰：BIBW2992治療鼻咽癌的臨床前研究 　　4. 吳階平醫(yī)學(xué)基金會(320672010015)：Notch信號對非小細(xì)胞肺癌EGFR通路的調(diào)節(jié)作用及聯(lián)合靶向治療的機(jī)制研究。(2010-2011)謝勉，張力(7萬) 　　5. 吳階平醫(yī)學(xué)基金會(320674010012)：測定晚期NSCLC患者EGFR-TKI治療前后外周血EGFR下游通路蛋白表達(dá)變化與預(yù)測EGFR-TKI治療療效價值的研究。(2010-2012)黃巖、趙洪云、趙媛媛、薛聰、張力(7萬) 　　6. 輝瑞制藥有限公司：c-met抑制劑在鼻咽癌中的體內(nèi)體外研究 　　2012年 　　1. 國家自然科學(xué)基金青年科學(xué)基金項目(81201718)：氟尿嘧啶相關(guān)酶調(diào)控作用下5FU劑量個體化治療模型的建立。(2013-2015)趙洪云、買世娟、趙媛媛、張劍威、黃巖、王志強(qiáng)、趙利平、田瑩、張力(23萬) 　　2. 廣東省科技計劃項目(2012B031800280): 轉(zhuǎn)錄共活化因子p300在非小細(xì)胞肺癌侵襲性發(fā)展中的作用。(2013-2015)侯雪、楊浩賢、張力、孫健、吳烜、薛聰、趙媛媛、徐理華、羅容珍、侯景輝(5萬) 　　3. 吳階平醫(yī)學(xué)基金會(?)：腫瘤相關(guān)炎癥因子對表皮生長因子受體-酪氨酸激酶抑制劑治療非小細(xì)胞肺癌耐藥的影響及機(jī)制探討。(2012-2014)吳烜，張力(5萬) 　　4. 廣東省自然科學(xué)基金(S2012040007455)：氟尿嘧啶相關(guān)酶調(diào)控作用下鼻咽癌5FU劑量個體化治療模型的建立。(2012-2014)趙洪云、張劍威、趙媛媛、黃巖、王志強(qiáng)、趙利平、田瑩、張力(3萬) 　　5. “863”高技術(shù)研究發(fā)展計劃資助重大項目：“重大疾病的分子分型與個體化診療技術(shù)”之“肺癌的分子分型和個體化診療技術(shù)”(2012AA02A502)(National High Technology Research and Development Program of China 2012AA02A502)子課題。張力、吳煊、胡志皇、方文峰、黃巖、趙洪云(30萬) 　　6. “863”高技術(shù)研究發(fā)展計劃資助重大項目：“重大疾病基因組技術(shù)”和“分子分型與個體化診療技術(shù)”之“鼻咽癌的分子分型和個體化診療技術(shù)”(2012AA02A501)(National High Technology Research and Development Program of China 2012AA02A501)子課題。張力、黃巖、吳煊、胡志皇、方文峰、趙洪云(50萬) 　　7. 國家科技重大專項項目：重大新藥創(chuàng)制之“基于高通量實時細(xì)胞篩選平臺和大容量化合物庫的新藥研發(fā)基地”(Innovative drug R&D center based on real-time high-throughput cell-based screening platformand large capacity compound library)之“分子靶點抗腫瘤新藥臨床研究”(2013ZX09401003-002)子課題。張力、李蘇、陳麗昆、趙洪云、趙媛媛、方文峰、畢炳添(200萬) 　　2013年 　　1. 吳階平基金課題(320.6750.1316)：外周血腫瘤細(xì)胞計數(shù)及耐藥相關(guān)分子改變動態(tài)監(jiān)測在EGFR突變陽性晚期非小細(xì)胞肺癌患者接受EGFR-TKI治療療效預(yù)測、評估及耐藥機(jī)制研究中的作用。張力、黃巖、方文峰、趙媛媛、吳煊、梁文華、田瑩、楊云鵬(200萬) 　　主編或編寫專著： 　　1.《實用頭頸腫瘤學(xué)》華南理工大出版社，1999年第一版，參加編寫， 　　2.《臨床腫瘤學(xué)》(高校教材)科學(xué)出版社，1999年第一版，2005年第二版，參加編寫，ISBN 7-03-015941-1 　　3.《社區(qū)腫瘤學(xué)》科學(xué)出版社，2000年第一版，參加編寫，2008年第二版，參加編寫 ISBN 978-7-03-022470-5 　　4.《腫瘤化療處方手冊》廣東科技出出版社，2003第一版，2005年第二版，主編 　　5.《腫瘤生物治療學(xué)》廣東科技出版社，2005第一版，參加編寫 　　6.《食道胃腸道癌》(中國抗癌協(xié)會科普系列叢書)人民衛(wèi)生出版社，2005第一版，參加編寫 　　7.《臨床腫瘤學(xué)》(國家級繼續(xù)醫(yī)學(xué)教育項目教材)中國醫(yī)學(xué)電子音像出版社，2006第一版，參加編寫 　　8.《腫瘤學(xué)專題講座》(名院學(xué)術(shù)廳叢書)鄭州大學(xué)出版社，2006第一版，參加編寫 ISBN 7-81106-266-6 　　9.《乳腺癌肺癌骨轉(zhuǎn)移診療規(guī)范建議-專家共識解讀》(中華醫(yī)學(xué)繼續(xù)教育視聽雜志)中國醫(yī)學(xué)電子音像出版社，ISBN 7-900191-80-1/R?80，2006;主講 　　10.《非小細(xì)胞肺癌規(guī)范診療進(jìn)展》(中華醫(yī)學(xué)繼續(xù)教育視聽雜志)中國醫(yī)學(xué)電子音像出版社，ISBN 978-7-900220-71-4/R?71，2007;主講 　　11.《惡性腫瘤骨轉(zhuǎn)移及骨相關(guān)疾病臨床診療專家共識》(2007年版)中國協(xié)和醫(yī)科大學(xué)出版社，ISRC CN-A37-07-0006-0/V.R(光碟版)，2007;主講 　　12.《惡性腫瘤骨轉(zhuǎn)移及骨相關(guān)疾病臨床診療專家共識》(2008年版)中國協(xié)和醫(yī)科大學(xué)出版社，ISRC CN-A37-08-0002-0/V.R(光碟版)，2008;主講 　　13.《惡性腫瘤骨轉(zhuǎn)移及骨相關(guān)疾病臨床診療專家共識》北京大學(xué)醫(yī)學(xué)出版社，2008年8月，第一版，ISBN 978-7-81116-125-0，參加編寫。 　　14.《腫瘤分子靶向治療》人民衛(wèi)生出版社，2009年5月，第一版，ISBN 978-7-711-11332-8，編委。 　　15.《臨床腫瘤學(xué)高級教程》(高級衛(wèi)生專業(yè)技術(shù)資格考試指導(dǎo)用書)　人民軍醫(yī)出版社，2011年11月，第一版，ISBN 978-7-5091-5170-9，編委。 　　16.《肺癌》張?zhí)m軍、張力主譯 　　17.《個體化醫(yī)學(xué)原則》人民衛(wèi)生出版社，2013年1月，第一版，ISBN 978-7-117-16476-4/R?16477，副主編。 　　2002-2011年發(fā)表論文: 　　第一作者或通訊作者： 　　1. 鼻咽癌患者血漿EB病毒DNA水平的動態(tài)變化與臨床療效的關(guān)系.《癌癥》2002, 21(8):817-822 　　2. HPLC法測定血漿中卡鉑的AUC.《中國臨床藥理學(xué)雜志》2002, 18(4)：294-296 　　3. 開普拓治療大腸癌的臨床應(yīng)用.《中華腫瘤雜志》2003,25(6):607-609 　　4. 吉西他濱加依托泊苷方案治療晚期非小細(xì)胞肺癌的II期臨床研究.《中國癌癥雜志》 2004, 14(1):59-60 　　5. 鼻咽癌患者血漿EB病毒DNA水平的動態(tài)變化與腫瘤復(fù)發(fā)關(guān)系.《臨床腫瘤學(xué)雜志》2004, 9(2):122-125 　　6. 晚期非小細(xì)胞肺癌組織中ERCC-1、Metallothionein、p53表達(dá)與鉑類耐藥性及預(yù)后的相關(guān)性分析.《癌癥》 2004, 23(7):845-850 　　7. 吉西他濱聯(lián)合順鉑與吉西他濱聯(lián)合諾維本治療晚期非小細(xì)胞肺癌的臨床研究.《癌癥》2004, 23(11s):1455-1458 　　8. 中國非小細(xì)胞肺癌患者表皮生長因子受體突變的研究.《癌癥》2005, 24(8):919-923 　　9. Li Zhang, Chong Zhao, Pei-Jian Peng, Li-Xia Lu, Pei-Yu Huang, Fei Han, and Shao-Xiong Wu: Preliminary Results of Randomized Phase III ClinicalStudy Comparing Standard Radiotherapy With orWithout Weekly Oxaliplatin in Treatment ofLocoregionally Advanced Nasopharyngeal Carcinoma. Journal of Clinical Oncology 2005; Vol 23(33): 8461-8468(SCI=11.81) 　　10. 晚期非小細(xì)胞肺癌治療新進(jìn)展.《中國肺癌雜志》 2005, 8(5):375-377 　　11. 吉西他濱聯(lián)合順鉑與吉西他濱聯(lián)合去甲長春堿方案治療非小細(xì)胞肺癌療效的比較.《中國肺癌雜志》 2005, 8(6):580-584 　　12. 組織微陣列方法分析晚期非小細(xì)胞肺癌患者HER2蛋白表達(dá)及其臨床意義.《中國肺癌雜志》2006, 9(1):50-54 　　13. Erlotinib在肺癌應(yīng)用中的相關(guān)分子和臨床預(yù)后指標(biāo).《循證醫(yī)學(xué)》2006, 6(1):10-13 　　14. 血漿EB病毒DNA濃度預(yù)測鼻咽癌遠(yuǎn)處轉(zhuǎn)移的研究.《癌癥》 2006, 25(7):785-792 　　15. 貝伐單抗與埃羅替尼聯(lián)合治療復(fù)發(fā)性非小細(xì)胞肺癌患者的I/II期臨床經(jīng)驗.《循證醫(yī)學(xué)》2006, 6(4):213-215 　　16. 國產(chǎn)多西紫杉醇治療晚期非小細(xì)胞肺癌的隨機(jī)對照臨床研究.《癌癥》2006, 25(8):999-1002 　　17. 重組人紅細(xì)胞生成素大劑量沖擊維持療法治療30例腫瘤相關(guān)貧血的臨床報告.《癌癥》 2006, 25(9):1120-1122 　　18. Gefitinib記名供藥計劃(EAP)治療晚期非小細(xì)胞肺癌患者的臨床研究結(jié)果.《癌癥》2006, 25(12):1561-1564 　　19. 原發(fā)性小腸腺癌 50例臨床分析.《臨床腫瘤學(xué)雜志》 2006, 11(5):358-360 　　20. 放射治療同期合并每周奧沙利鉑治療局部晚期鼻咽癌的隨機(jī)Ⅱ期臨床對照研究.《中國腫瘤臨床》 2006, 33(17):995-998 　　21. 非小細(xì)胞肺癌輔助化療的熱點問題.《中華結(jié)核和呼吸雜志》2007, 30(2):86-87 　　22. Bijesh Raj Ghimire，林立平，郭穎，張力:同期化放療與單純放療在局部晚期鼻咽癌中的作用：一項關(guān)于III期隨機(jī)試驗的薈萃分析.《循證醫(yī)學(xué)》2007, 6(4):213-215 　　23. 吉非替尼治療化療失敗的局部晚期或轉(zhuǎn)移性非小細(xì)胞肺癌療效及生存的預(yù)測因素.《中國肺癌雜志》 2007, 10(5):411-417 　　24. Li Zhang, Yang Zhang, Pei-Yu Huang, Fei Xu, Pei-Jian Peng, Zhong-Zhen Guan: Phase II Clinical Study of Gemcitabine in the treatment of patients withadvanced nasopharyngeal carcinoma (NPC) after the failure of platinumbased chemotherapy. Cancer Chemotherapy and Pharmacology2008; Vol 61(1):33-38(SCI=2.2) 　　25. 應(yīng)用熒光原位雜交方法檢測鼻咽癌細(xì)胞系中 EGFR基因拷貝數(shù)變化.《實用癌癥雜志》2008, 23(4):390-392 　　26. 晚期非小細(xì)胞肺癌一線化療療效與生存關(guān)系的分析.《中國肺癌雜志》2008, 11(3):333-338 　　27. 晚期非小細(xì)胞肺癌的二線治療進(jìn)展.《中國肺癌雜志》 2008, 11(1):4-9 　　28. 厄羅替尼治療晚期非小細(xì)胞肺癌患者的臨床療效.《癌癥》 2008, 27(4):393-399 　　29. 非小細(xì)胞肺癌小腸轉(zhuǎn)移1例報告和文獻(xiàn)復(fù)習(xí).《癌癥》2008, 27(4):447-448 　　30. 化療在不可切除III期(N2)非小細(xì)胞肺癌中的作用.《中國肺癌雜志》 2008, 11(5):657-662 　　31. Relationship between expression of CEA, E-cadherin and liver metastasis in colorectal cancer. Chinese Journal of Clinical Oncology 2008; Vol 5 (6):429-432 　　32. 組織芯片技術(shù)分析c-kit蛋白在鼻咽癌組織中的表達(dá)及其臨床意義 .《臨床腫瘤學(xué)雜志》2009, 14(2):97-101 　　33. C-KIT基因在鼻咽癌患者中的突變.《中國癌癥雜志》2009, 19(4):266-269 　　34. 鼻咽、肺雙原發(fā)癌一例病例報告和文獻(xiàn)復(fù)習(xí).《中國肺癌雜志》 2009, 12(1):86-89 　　35. 吉非替尼對鼻咽癌細(xì)胞抑制作用及其對 EGFR 表達(dá)影響的探討.《中華腫瘤防治雜志》 2009, 16(13):978-981 　　36. Xu Fei, Li Su, Li Xiao-ling, Guo Ying, Zou Ben-Yan, Xu Ran, Liao Hai, Zhao Hong-Yun, Guan Zhong-Zhen, Zhang Li: Phase I study of Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and Ganciclovir administration in patients with malignant tumor. Cancer Gene Therapy 2009; Vol 16:723-730(SCI=3.89) 　　37. Li Zhang, Xue Hou, Shun Lu, Huilan Rao, Jinghui Hou, Rongzhen Luo,He Huang, HongyunZhao, Hong Jian, Zhiwei Chen, Meilin Liao, Xin Wang: Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study. Lung Cancer 2010; Vol 67:114-119(SCI=3.14) 　　38. 鼻咽癌細(xì)胞株中C-Kit表達(dá)和突變以及對Imatinib的反應(yīng)性.《癌癥》 2010; 29(2):137-142 　　39. Wei Jiang, Yang Zhang, Hongyun Zhao, Guangchuan Xu, Liping Lin, Yuanyuan Zhao, Cong Xue, Li Zhang:Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer.Chinese Journal of Lung Cancer2010;Vol 13(3):211-215 　　40. RRM1和 ERCC1對早期非小細(xì)胞肺癌術(shù)后生存的預(yù)測作用. 《循證醫(yī)學(xué)》 2010, 10(1):17-22 　　41.非小細(xì)胞肺癌患者K-RAS基因突變的研究.《中國肺癌雜志》2010, 13(6):602-606 　　42. Wang, Fenghua; Jiang, Fanggong; Li, Yuhong; Guo, Ying; Shen, Lin; Zhang Li:The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in AdvancedGastric Cancer: A Systematic Review and Pooled Analysis of theChinese Literature. Current Cancer Therapy Reviews 2010;Vol 6 (3):214-221. 　　43. Liang-ping Xia; Hui-juan Qiu; Xu-xian Chen; Pi-li Hu; Gui-fang Guo; Fang Wang; Fei-fei Zhou; Wen-zhuo He; Bei Zhang; Li Zhang: Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Medical Oncology2010; Vol28(1):570-576 (SCI=1.227) 　　44. Li Zhang, Chong Zhao, Bijesh Ghimire, Ming-Huang Hong, Qing Liu, Yang Zhang, Ying Guo,Yi-Jun Huang, Zhong-Zhen Guan：The Role of Concurrent Chemoradiotherapy in the Treatment of Locolregionally Advanced Nasopharyngeal Carcinoma among Endemic Population: A Meta- analysis of the Phase III Randomized Trials. BMC Cancer 2010; Vol 10:558 (SCI=2.74) 　　45. Li Zhang, Su Li, Yang Zhang, Jing Zhan, Ben-Yan Zou, Robert Smith, Paul D Martin, Yinrui Jiang, Hai Liao, Zhong-zhen Guan: Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumours: An Open-Label, Phase I, Rising Multiple Dose Study. ClinicalTherapeutics, 2011; Vol 33(3): 315–327 (SCI=3.28) 　　46.Xue Hou, Chong Zhao, Ying Guo, Fei Han, Li-Xia Lu, Shao-Xiong Wu, Su Li, Pei-Yu Huang, He Huang, Li Zhang:Different Clinical Significance of Pre- and Post-treatment Plasma Epsteine Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy. Clinical Oncology 2011; Vol 23: 128-133 (SCI=2.85) 　　47.Yuan-Yuan Zhao, Cong Xue, Xue Hou, Hai Liao, Su Li, Hong-Yun Zhao, YanHuang, Li-Kun Chen, Fei Xu, Jun-Ling Liu, Li Zhang: Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. European Journal of Cancer 2011; Vol 47:848-853 (SCI=4.47) 　　48.Fenghua Wang, Yang Zhang, Hongyun Zhao, Likun Chen,Yan-Xia Shi, Li Zhang:Validation of a clinical prognostic modelinChinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.Medical Oncology 2011; Vol28(1):331-5(SCI=2.21) 　　49.Yuan-Yuan Zhao, Su Li, Yang Zhang, Hong-Yun Zhao, Hai Liao, Ying Guo, Yan-Xia Shi, Wei Jiang, Cong Xue, Li Zhang:The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Medical Oncology 2011; Vol 28(3):697-702(SCI=2.21) 　　50.Yuan-Yuan Zhao, Cong Xue, Wei Jiang, Hong-Yun Zhao, Yan Huang, Kristin Feenstra, James H. Resau, Chao-Nan Qian, Li Zhang:Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.Journal of Thoracic Oncology2012; Vol 7(1):71-75(SCI=3.66) 　　51. Li Zhang, Shenglin Ma, Xiangqun Song, Baohui Han, Ying Cheng, Cheng Huang, Shujun Yang, Xiaoqing Liu, Yunpeng Liu, Shun Lu, Jie Wang, Shucai Zhang, Caicun Zhou, Xiangwei Zhang, Nobuya Hayashi, Mengzhao Wang: Efficacy and tolerability data from a randomised, placebo-controlled, parallel-group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) Lancet Oncology 2012;Vol 13:466-475 (SCI=22.589) 　　52.Pei-Yu Huang, Yan Li, Hai-Qiang Mai, Rong-Zhen Luo, Yu-Chen Cai, Li Zhang: Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncology 2012; Vol 48(10):964-968 (SCI=2.857) 　　53. Cong Xue, Zhihuang Hua, Wei Jiang, Yuanyuan Zhao, Fei Xu, Yan Huang, Hongyun Zhao, Jingxun Wu, Yang Zhang, Liping Zhao, Jing Zhang, Likun Chen, Li Zhang: National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 2012; Vol 77(2):371-375 (SCI=3.43) 　　54. Cong Xue, Xi Wang, Roujun Peng, Yanxia Shi, Tao Qin, Donggen Liu, Xiaoyu Teng, Shusen Wang, Li Zhang and Zhongyu Yuan: Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Science 2012;Vol 103(9):1679-1687(SCI=3.325) 　　55. Yang Zhang, Liping Zhao, Peiyu Huang, Jingxun Wu, Fenghua Wang, Yan Huang, Li Zhang: Open-Label Single-Arm Phase II Study of Pemetrexed in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Had Prior Platinum Based Chemotherapy. Cancer Chemotherapy and Pharmacology2012; Vol 70(4):611-615(SCI=2.2) 　　56.Jianwei Zhang, Yan Huang, Xiaoling Li, Ying Guo, Yuanyuan Zhao, Cong Xue, Zhihuang Hu, Li Zhang, Hongyun Zhao: The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLCfrom one institution. Onco Targets and Therapy 2012, Vol 5:349–355 (SCI=1.26) 　　57. Fei Xu, Jingxun Wu, Yuanyuan Zhao, Cong Xue, Wei Jiang, Liping Lin, Xuan Wu, Yachao Lu, Hua Bai, Jiasen Xu, Guanshan Zhu, Li Zhang: Comparison of different methods for detecting epidermal growth factor receptor mutationsin peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets and Therapy 2012, Vol 5:439-447 (SCI=1.26) 　　58. Yan Huang, Jing Zhang, Yuan-Yuan Zhao, Wei Jiang, Cong Xue, Fei Xu,Hong-Yun Zhao, Yang Zhang, Li-Ping Zhao, Zhi-Huang Hu, Zhi-Wen Yao,Qian-Yong Liu and Li Zhang: SPARC expression and prognostic value in non-small cell lung cancer. Chinese Journal of Cancer 2012; Vol31(11):541-548 　　59. Zhao LP, Xue C, Zhang JW, Hu ZH, Zhao YY, Zhang J, Huang Y, Zhao HY, Zhang L. Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma. Chin J Cancer. 2012 Oct;31(10):476-8362. 　　60. Hongyun Zhao, Yan Huang, Cong Xue,Yang Chen, Xue Hou, Ying Guo,Liping Zhao, Zhi huang Hu, Yujie Huang, Yongzhang Luo, Li Zhang: Prognostic significance of cell surface nucleolin expression in postoperative non-small cell lung cancer. PLos One 2013; Vol 8(1):e54674 (SCI=4.09) 　　61.C. Xue, Y. Huang, P. Y. Huang, Q. T. Yu, J. J. Pan, L. Z. Liu, X. Q. Song, S. J. Lin, J. X. Wu, J. W. Zhang, H. Y. Zhao, F. Xu, J. L. Liu, Z. H. Hu, L. P. Zhao, Y. Y. Zhao, X Q . Wu, J. Zhang, Y. X. Ma,2&L. Zhang：Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Annals of Oncology 2013; Vol 24:1055-1061 (SCI=7.384) 　　62.X. Wu, P. Y. Huang, P. J. Peng, L. X. Lu, F. Han, S. X. Wu, X. Hou, H. Y. Zhao, Y. Huang, W. F. Fang, Y. Y. Zhao, C. Xue, Z. H. Hu, J. Zhang, J. W. Zhang, Y. X. Ma, W. H. Liang, C. Zhao, L. Zhang: Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Annals of Oncology 2013 Aug;24(8):2131-6; (SCI=7.384) 　　63. Hongyun Zhao, Yuanyuan Zhao, Ying Guo, Yan Huang, Suxia Lin, Cong Xue, Fei Xu, Yang Zhang, Liping Zhao, Zhihuang Hu, Li Zhang.: Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. Onco Targets and Therapy2013; Vol 6:811-818 (SCI=2.073) 　　64. Jian-Wei Zhang, Yuan-Yuan Zhao, Ying Guo, Cong Xue, Zhi-Huang Hu, Yan Huang, Hong-Yun Zhao, Jing Zhang, Xuan Wu, Wen-Feng Fang, Yu-Xiang Ma, Li Zhang.: The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of advanced non--small cell lung cancer. Chinese journal of cancer 2013;Vol 32(1): (Accepted) 　　65. Yuankai Shi*, Li Zhang (1)*, Xiaoqing Liu,et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013 Sep;14(10):953-61 (IF 22.589) 　　66. Xuan Wu,Wenhua Liang,Xue Hou,Zhong Lin,Hongyun Zhao,Yan Huang,Wenfeng Fang,Yuanyuan Zhao,Jinxun Wu,Yunpeng Yang,Cong Xue,Zhihuang Hu,Jing Zhang,Jianwei Zhang,Yuxiang Ma,Ting Zhou,Tao Qin, LiZhang*. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. OncoTargets and Therapy 2013:6 1481–1491 (IF 2.073) 　　67. Wenfeng Fang，Jianwei Zhang，Wenhua Liang，Yan Huang，Yue Yan，Xuan Wu，Zhihuang Hu，Yuxiang Ma，Hongyun Zhao，Yuanyuan Zhao，Yunpeng Yang，Cong Xue，Jing Zhang，LiZhang* Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis 2013;5(5):585-592 　　第二、三作者及其他： 　　1. E1B缺失腺病毒瘤內(nèi)注射治療惡性腫瘤的安全性研究.《癌癥》2003, 22(3):310-313 　　2. 423例非小細(xì)胞肺癌患者生存的多因素分析.《癌癥》2003, 22(6):624-628 　　3. 表皮生長因子酪氨酸激酶抑制劑ZD1839對鼻咽癌細(xì)胞系的作用.《癌癥》2004, 23(5)：540-544 　　4. 表皮生長因子酪氨酸激酶抑制劑Gefitinib對鼻咽癌荷瘤裸鼠移植瘤生長作用的實驗研究.《癌癥》2004, 23(11s)：1365-1369 　　5. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng Xiao: Phase III randomized Clinical Trial of Intratumoral Injection of E1B Gene-deleted Adenovirus (H101) Combined with Cisplatin-based Chemotherapy in Treating Squamous Cell Cancer of Head and Neck or Esophagus. Chinese Journal of Cancer 2004; Vol 23(12):1666-1670 　　6. 雌、孕激素受體在乳腺癌原發(fā)灶及復(fù)發(fā)轉(zhuǎn)移灶之間的表達(dá)差異.《癌癥》2004, 23(12)：1710-1713 　　7. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.Comparison of Plasma Epstein–Barr Virus (EBV) DNA Levels and Serum EBV Immunoglobulin A/Virus Capsid Antigen Antibody Titers in Patients with Nasopharyngeal Carcinoma. Cancer 2004;100:1162–70(SCI=4.8) 　　8. Chen M, Chen YY, Bao Y, Xian CG, Liu GZ, Zhang L, Xu GC, Deng XW, Lu TX, Qian JY, Cui NJ. Neoadjuvant Chemotherapy Followed by Late-Course Accelerated Hyperfractionated Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Long-Term Results of a Phase I/II Clinical Trial. Clinical Lung Cancer 2005, Vol 6(5):304-309(SCI=2.3) 　　9. 羥基喜樹堿在腫瘤病人中的生物利用度研究.《中國臨床藥理學(xué)雜志》2005, 22(1):46-49 　　10. Tony S.K. Mok, Kwok Chi Lam, Conrad Lee,Li Zhang, Herman Wong,Anthony T.C. Chan, Winnie Yeo, Anthony P.C. Yim, Karen Chak, Benny Zee: Phase II Randomized Study Comparing theToxicity Profile of Gemcitabine plus Cisplatin withGemcitabine plus Oral Etoposide in the Treatmentof Advanced Non-Small Cell Lung Cancer. Oncology 2005; Vol 68:485-492(SCI=1.9) 　　11. 吉非替尼治療局部晚期或轉(zhuǎn)移性非小細(xì)胞肺癌在中國的臨床研究.《癌癥》2005，24(8)：980-984 　　12. 結(jié)直腸癌患者 DPD 水平與 5-FU血藥濃度療效及毒性的相關(guān)性研究.《癌癥》2005，24(4)：483-487 　　13. 柯薩奇病毒腺病毒受體的表達(dá)對基因工程腺病毒抗瘤活性的影響.《癌癥》2005，24(4)：502-505 　　14. 116例攜帶乙肝病毒的淋巴瘤患者化療后發(fā)生肝功能損害的臨床分析.《癌癥》2005，24(12)：1507-1509 　　15. 膀胱癌細(xì)胞CAR 的表達(dá)對E1B缺失腺病毒抗瘤活性的影響.《中山大學(xué)學(xué)報》2005，26(9)：533-536 　　16. Li YH, He YF, Jiang WQ, Wang FH, Lin XB,Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.Cancer2006;106(6):1320-1325 (SCI=4.58) 　　17. Fu Xiao-Hong, Wang Shu-Sen, Huang Yan, Wang Bo, Huang Hui-Qiang, Zhang Li, Sun Xiao-Fei, Xu Rui-Hua, Lin Tong-Yu: Feasibility Study of Application of International Prognostic Score on Prediction of Prognosis of Advanced Hodgkin’s Lymphoma. Chinese Journal of Cancer 2006; Vol 25(8):1013-1018 　　18.鼻咽癌組織中EGFR和p-ERK蛋白表達(dá)及檢測意義.《中華腫瘤雜志》2006，28(1)：28-31 　　19.誘導(dǎo)化療和紫杉醇每周同期化療結(jié)合三維適形放射治療不能手術(shù)的Ⅲ期非小細(xì)胞肺癌的初步結(jié)果.《癌癥》2006, 25( 10) : 1279- 1283 　　20. 支氣管肺泡細(xì)胞癌之中國共識.《循證醫(yī)學(xué)》2006, 6( 4) : 227- 230 　　21. 老年晚期非小細(xì)胞肺癌預(yù)后的影響因素分析.《廣州醫(yī)學(xué)院報》2007, 35( 5) : 48- 52 　　22. CPT-11聯(lián)合 5-FU/CF(FOLFIRI)化療方案治療晚期結(jié)直腸癌.《 癌癥》 2007, 26( 8) : 905- 908 　　23. 非小細(xì)胞肺癌孤立性轉(zhuǎn)移處理共識.《循證醫(yī)學(xué)》2007, 7(2):110-111 　　24. Wu YL, Zhong WZ, Li LY, Zhang XT,Zhang L,Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T:Epidermal Growth Factor Receptor Mutations and TheirCorrelation with Gefitinib Therapy in Patients withNon-small Cell Lung Cancer: A Meta-Analysis Based onUpdated Individual Patient Data from Six Medical Centersin Mainland China. Journal of Thoracic Oncology 2007; Vol 2: 430–439 (SCI=1.43) 　　25. FOLFOX 方案一線治療轉(zhuǎn)移性或復(fù)發(fā)性晚期大腸癌的療效分析.《中國腫瘤臨床》 2007, 34(24):1418-1421 　　26. 吉西他濱聯(lián)合奧沙利鉑治療晚期胰腺癌患者的療效.《癌癥》2007，26(12)：1381-1384 　　27. 105例老年晚期非小細(xì)胞肺癌患者的回顧性分析.《臨床腫瘤學(xué)雜志》2008,13(5):409-412 　　28. 非小細(xì)胞肺癌ⅢA期 N2 之處理.《循證醫(yī)學(xué)》2008，8(2)：113-117 　　29. Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ:A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer.Chemotherapy 2008; Vol 54:228-235 (SCI=1.50) 　　30. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM,Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chui W, Lee JS:Randomized, Placebo-controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2009; Vol 27:5080-5087 (SCI=17.3) 　　31. Mok T, Wu YL, Zhang L: A small step towards personalized medicine for non-small cell lung cancer.Discov Med. 2009;Vol 8(43):227-31 　　32. 孤立性肺結(jié)節(jié)的處理.《循證醫(yī)學(xué)》2009，9(4)：244-246 　　33. FOLFIRI 方案對草酸鉑治療失敗的晚期結(jié)直腸癌的療效分析.《癌癥》2009;Vol 28(9):913-918 　　34. 局部晚期鼻咽癌誘導(dǎo)加同期化放療與誘導(dǎo)化放療的對照研究.《癌癥》2009;Vol 28(10):1033-1042 　　35. Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K:Efficacy and Safety of Erlotinib in 1240 East/South-East Asian Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2010; Vol 5: 1609-161 (SCI=4.547) 　　36. 貝伐珠單抗治療非小細(xì)胞肺癌的相關(guān)不良反應(yīng)及處理原則.《中國肺癌雜志》2010，13(6)：563-567 　　37. 局限期小細(xì)胞肺癌放療靶區(qū)前瞻性隨機(jī)對照研究的初步報告.《中國肺癌雜志》 2010，13(7)：691-6 　　38. 紫杉醇聯(lián)合順鉑每周方案與三周方案治療老年晚期非小細(xì)胞肺癌的臨床隨機(jī)對照研究.《中國腫瘤防治雜志》 2010，17(18)：1463-1466 　　39. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S,Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE:Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer: a randomised, double-blind phase III trial (ZODIAC). Lancet Oncology 2010;Vol 11: 619–26 (SCI= 14.47) 　　40.Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology 2011;Vol 12:735-742 (SCI= 17.76) 　　41.An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH:Plasma Epstein-Barr virus DNA level strongly predicts survival inmetastatic/recurrentnasopharyngeal carcinoma treated with palliativechemotherapy.Cancer2011;Vol 117(16):3750-7. (SCI=5.131) 　　42. Hu X, Bao Y, Zhang L, Guo Y, Chen YY, Li KX, Wang WH, Liu Y, He H, Chen M:Omitting elective nodal irradiation and irradiating postinduction versuspreinduction chemotherapy tumor extent for limited-stage small cell lung cancer: Interim analysis of a prospective randomized non-inferiority trial.Cancer2012; Vol 118(1):278-287 (SCI= 5.131) 　　43.Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, Zhao LP, Tian Y:Activation of Notch-1 enhances epithelial-mesenchymal transition ingefitinib-acquired resistant lung cancer cells. J Cell Biochem.2012, Vol 113(5):1501-1513 (SCI= 3.12) 　　44. Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M:Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Carein Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer:An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial.Journal of Thoracic Oncology 2012; Vol 7(3):567-573 　　45. Mian Xie, Li Zhang, Chao-Sheng He, Jin-Hui Hou, Su-Xia Lin, Zhi-Huang Hu, Fei Xu and Hong-Yun Zhao: Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2012; Vol 7(5):799-807 　　46. Luis Paz-Ares, Bonne Biesma, David Heigener, Joachim von Pawel, Timothy Eisen, Jaafar Bennouna, Li Zhang, Meilin Liao, Yan Sun, Assad Chemaissani, SJM Gans, Constantinos Syrigos, Etienne Le Marie, Maya Gottfried, Johan Vansteenkiste, Vincente Alberola, Uwe Phillip Strauss, Elaine Montegriffo, Teng Jin Ong, Armando Santoro, on behalf of the NExUS Investigators Study Group: Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/ Cisplatin Alone or with Sorafenib for the First-Line Treatment of Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology 2012; Vol 30:3048-3092 (SCI=18.37) 　　47. Yin-Duo Zeng, Li Zhang, Hai Liao, Ying Liang, Fei Xu, Jun-Ling Liu, Xiao-Xiao Dinglin, Li-Kun Chen: Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.Asian Pacific journal of cancer prevention2012; Vol 13(3):909-914.(SCI=0.66) 　　48. Y. Sun, Y.-L. Wu, C.-C. Zhou, L. Zhang, L. Zhang, X.-Y. Liu, S.-Y. Yu, G.-L. Jiang, K. Li, S.-K. Qin, S.-L. Ma, L. Han, M. Quinlivan, M. Orlando, X.-Q. Zhang: Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study. Lung Cancer2013; Vol 79(2):143-50, (SCI=3.43) 　　49. Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M.: Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol. 2012; Vol 8(3):232-243 (SCI=0.58) 　　50. 吉西他濱聯(lián)合長春瑞濱方案一線治療中國晚期非小細(xì)胞肺癌患者的多中心回顧性研究?！吨袊伟╇s志》2012; Vol 15(5):281-6. 　　51. 吉西他濱聯(lián)合長春瑞濱方案治療復(fù)治中國晚期非小細(xì)胞肺癌患者的多中心回顧性研究。《中國肺癌雜志》2012; 15(9):507-12. 　　52. Fang Wang, Sha Fu, Qiong Shao, Yan-Bin Zhou, Xiao Zhang, Xu Zhang, Cong Xue, Jian-Guang Lin,Li-Xia Huang, Li Zhang, Wei-Min Zhang and Jian-Yong Shao：High EGFR copy number predicts benefits fromtyrosine kinase inhibitor treatment for non-smallcell lung cancer patients with wild-type EGFR. Journal of Translational Medicine 2013, Vol 11:90 (SCI=3.47) 　　53. G. Chen, J. Feng, C. Zhou, Y.-L. Wu, X.-Q. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou,S. Ren3, S. Lu, L. Zhang, C.-P. Hu, C. Hu, Y. Luo, L. Chen, M. Ye, J. Huang,X. Zhi, Y. Zhang, Q. Xiu, J. Ma, L. Zhang & C. You: Quality of life (QoL) analyses from OPTIMAL(CTONG-0802), a phase III, randomised, open-labelstudy of first-line erlotinib versus chemotherapy inpatients with advanced EGFR mutation-positivenon-small-cell lung cancer (NSCLC). Annals of Oncology, 2013 (SCI=7.384, Accepted) 　　54. Yi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, Chong-Jen Yu, Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Fatima Fuerte, Gee-Chen Chang, Kasan Seetalarom, Jie Wang, Ashley Cheng, Elisna Syahruddin, Xiaoping Qian, James Ho, Johan Kurnianda, Hsingjin Eugene Liu, Kate Jin, Matt Truman, Ilze Bara, Tony Mok：Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncology 2013;Vol 14(8):777-786 (SCI=25.117) 　　55.會議摘要(2003-2012)： 　　1. L. Zhang, P.J. Peng, C. Zhao: Randomized Phase II clinical study comparing standard RT with or without weekly Oxaliplatin in treatment of locally advanced NPC: preliminary result. Proc Am Soc Clin Oncol 2003; Vol 21:2003a (Poster) 　　2. L. Zhang, Y. Zhang, ZZ. Guang: Phase II clinical study of Gemcitabine single agent for patients with advanced Nasopharyngeal Carcinoma (NPC) who failed to first line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2004; Vol 22:5612a (Poster) 　　3. L. Zhang, X. Zhang, ZK.Pan, X.Wang, N.Li, F. Xu, JH.Chang, ZZ. Guang: The status of epidermal growth factor receptor (EGFR) mutations at exon 19 and 21 in Chinese patients with NSCLC. Proc Am Soc Clin Oncol 2005; Vol 23:7097a (Poster) 　　4. Y. Zhang, L. Zhang, N. Li, F. Xu, ZK. Pan, ZZ. Guang: Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005; Vol 23:7329a (Poster) 　　5. Z Guan, L Zhang, L LI, G Jiang, X LIU, D Chu, W Li: A Chinese, Multicentre, Phase II Trial of Gefitinib (Iressa) in Patients with non-Small-Cell Lung Cancer who had Failed Previous Chemotherapy. 11th WCLC, Barcelona, Spain, July 3-6, 2005; Ab 2264 　　6. L. Zhang, Li Ning, Zhang Xing, Pan Zhen-kui, Wang Xin, Xu Fei, Zhong-zhen Guan: Preliminary Analysis of biomarkers in plasma by SELDI to predict the response to EGFR Tyrosine Kinase Inhibitors (TKIs) in NSCLC patients. Proc Am Soc Clin Oncol 2006; Vol 24:7189a (Poster) 　　7. Xu Fei, Zhang Li, Li Su, Liao Hai: Phase I study of Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and Ganciclovir administration in patients with malignant tumor. AACR 2007, Ab 1888 　　8. B.R.Ghimire, L. Zhang, X. Zhang, S. Li, X. Hou, P.J. Peng: Effects of zoledronic acid on proliferation and synergy with cytotoxic agents in nasopharyngeal carcinoma cell lines. AACR 2007, Ab 3137 　　9. X. Hou,L. Zhang, C. Zhao, L. Lu, F. Han, S. Li, P. Huang, H. Huang, Z. Guan: Clinical significance of Epstein-Barr virus DNA load detected pre- and post-radiotherapy in nasopharyngeal carcinoma patients. Proc Am Soc Clin Oncol 2007; Vol 25:10558a(Poster) 　　10. L. Zhang, X. Hou, H. Rao, J. Hou, R. Luo, H. Huang, P. Huang: Predictive significance of bone sialoprotein and osteopontin for bone metastases in respectable non-small cell lung cancer: A retrospective study. Proc Am Soc Clin Oncol 2007; Vol 25:7666a (Poster) 　　11. R. Xu, B. Han, Y. Shi, J. Xiong, Y. Li, F. Wang, M. Qiu, W. Jiang, T. Lin, L. Zhang, Y. He: Phase II clinical trial of XELOX as first line treatment for patients with unresectable or metastatic gastric cancer. Proc Am Soc Clin Oncol 2007; Vol 25:15062a(Publication) 　　12. Y. Wu, L. Zhang, J. Siu-Kie Au, A. Cheng, K. Park, H. Kim, V. Srimuninnimit, V. Sriuranpong, M. Lin, H. Kuo, on behalf of the Asia Pacific TRUST investigators: Safety of erlotinib in TRUST, a phase IV trial in patients with advanced non-small cell lung cancer (NSCLC): Initial results from the East/South East (E/SE) Asian subgroup. Proc Am Soc Clin Oncol 2007; Vol 25:18018a(Publication) 　　13. Lin Li-Shan, Zhang Li, Zhang Yang, Wang Zhi-Qiang, Huang He, Zhao Hong-Yun, Guan Zhong-Zhen. Predictive factors of efficacy and survival in Chinese non-small cell lung cancer patients treated with gefitinib. Journal of Thoracic Oncology 2007; Vol 2:S748(Poster) 　　14.L. Zhang, C. Zhao, B. R. Ghimire, Y. Guo, Z. Z. Guan: The Role of Concurrent Chemo-radiation in the Treatment of Locally Advanced Nasopharyngeal Carcinoma among Endemic Area: A Meta- analysis of the Phase III Randomized Trials. Proc Am Soc Clin Oncol 2008; Vol 26:6032a (Poster Discussion) 　　15. J. S. Lee, J. Ignacio, C. Yu, C. Zhou, Y. Wu, Y. Chen, L. Zhang, K. Jin, M. Johnston, T. S. Mok.:FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008; Vol 26:8031a (Poster Discussion) 　　16. K. Lam, T. S. Mok, J. Lee, L. Zhang, Y. Wu, S. Lu, M. Liao, C. Yang, C. Zhou, M. Boyer.: A randomized phase II study of gemcitabine (G) vs gemcitabine/carboplatin (GC) as consolidation therapy to concurrent chemo-radiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC): A Lung Cancer Research Group (LCRG) study. Proc Am Soc Clin Oncol 2008; Vol 26:7559a (Poster) 　　17. Y. Y. Zhao, C. Q. Zhang, L. P. Lin, X. Wu, J. X. Wu, F. H. Wang, H. Y. Zhao, Z. Z. Guan, L. Zhang: The relationship between circulating VEGF level and outcome of advanced Chinese NSCLC treated with gefitinib. Proc Am Soc Clin Oncol 2008; Vol 27:19074a (Publication) 　　18. J. X. Wu, H. Y. Zhao, Y. Zhang, Z. Z. Guan, L. Zhang: The relationship between change in tumor size and survival in advanced NSCLC treated with gefitinib. Proc Am Soc Clin Oncol 2008; Vol 26:19066a (Publication) 　　19. L. Zhang, F.H. Wang, Y.H. Li, Y.J. He, Y. Guo, Z.Z. Guan: The role of oxaliplatin- containing regimens in the treatment of Chinese patients with advanced gastric cancer: a meta-analysis of randomized trials. ESMO 2008, (Poster 534) 　　20. Y. Wu, T. Mok, D. Chu, B. Han, X. Liu, L. Zhang, C. Zhou, Y. Rukazenkov, E. Duffield, M. Fukuoka: Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Proc Am Soc Clin Oncol 2009; Vol 27:8041a (Poster) 　　21. Y. Zhao, H. Liao, X. Hou, J. Sun, Y. Guo, S. Li, L. Zhang: A prospective, open-label, randomized phase II trial to evaluate the changes of bone resorption marker after administration of zoledronic acid (ZOL) in nasopharyngeal cancer (NPC) patients with bone metastases (BM). Proc Am Soc Clin Oncol 2009; Vol 27:6063a (Poster) 　　22.J. Wu, H. Bai, G. Zhu, J. Xu, W. Jiang, L. Lin, C. Xue, L. Zhang: Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood as a predictor of response to gefitinib.Proc Am Soc Clin Oncol 2010; Vol 28:10557a (Poster) 　　23.W. Huang, J. Wu, X. Lin, S. Li, R. Liu, W. Hu, Y. Xia, L. Zhang, W. Jiang, Z. Guan: A multicentre, open-label, randomized phase II trial of adenovirus-mediated endostatin gene therapy in combination with paclitaxel and cisplatin chemotherapy in advanced head and neck carcinoma: Preliminary results.Proc Am Soc Clin Oncol 2010; Vol 28: e16005(Publication) 　　24.L. Zhang, S. Y. Yu, G. R. Xie, B. Xu, Z. Jiang, S. Lu, H. Wang, Y. Sun; A large, multicenter, retrospective epidemiological survey the incidence and treatment of bone metastatic disease in Chinese cancer patients. Proc Am Soc Clin Oncol 2010; Vol 28:e19612(Publication) 　　25.H. Zhao, G. Chen, J. F. Feng, Y. Chen, Y. Zhang, X. Song, Y. Huang, L. Zhang; A phase II study of erlotinib plus capecitabine (XEL) as first line treatment for elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study).Proc Am Soc Clin Oncol 2010; Vol 28:e18016(Publication) 　　26.L. Zhang, M. Shenglin, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Q. Liu, L. Yun-Peng, M. Wang, X. Zhang: Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) in China (INFORM) (C-TONG 0804). Proc Am Soc Clin Oncol 2011; Vol 29:LBA7511 (Oral) 　　27.Y. Cheng, L. Zhang, H. Zhang, C. Zhou, B. Han, Y. Zhang, C. Huang, J. H. Chang, X. Song, J. Liang, H. Liang, J. Hu, S. Y. Yu, J. Chen, J. Wang, H. M. Pan, A. Carides, D. Chitkara: A 3-day oral aprepitant regimen provides superior prevention of CINV over standard therapy in Chinese patients receiving high-dose cisplatin. Proc Am Soc Clin Oncol 2011; Vol 29:9105 (Poster) 　　28.Y. Sun, Y. Shi, L. Zhang, X. Q. Liu, C. Zhou, L. Zhang, D. Wang, Q. Li, S. Zhang, S. Qin, C. Hu, Y. Zhang, J. Chen, Y. Song, J. F. Feng, Y. Cheng, H. Zhang, Y. L. Wu, N. Xu, J. Zhou: A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).Proc Am Soc Clin Oncol 2011; Vol 29:7522(Poster) 　　29.S. Lu, L. Zhang, Y. L. Wu, Y. Zhang, C. Zhou, G. Chen, M. Hou, X. Song, J. Wang：An observational study on the efficacy and safety of zoledronic acid (ZA) in non-small cell lung cancer (NSCLC) patients with bone metastases with high urine n-telopeptide (uNTX) at diagnosis (C-TONG 0801).Proc Am Soc Clin Oncol 2011; Vol 29: e19541(Publication) 　　30.C. Zhou, Y. L. Wu, G. Chen, J. F. Feng, X. Q. Liu, C. L. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang：Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).Proc Am Soc Clin Oncol 2011; Vol 29:7520(Poster) 　　31. Yi-long Wu, Caicun Zhou, Li Zhang, Reury-Perng Perng, Tony Mok: Efficacy of erlotinib across clinical subgroups in Chinese patients and a broader Asian subpopulation with advanced non-small-cell lung cancer (NSCLC): sub-analysis of the TRUST study. Journal of Thoracic Oncology 2011; (ab P3.102) (Poster) 　　32.C. Xue, J. J. Pan, X. Song, Y. Zhang, Q. Yu, S. Lin, J. Wu, Y. Zhao, W. Jiang, L. Zhang: Phase II study of combination of sorafenib with cisplatin and 5-fluorouracil as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 2012;Vol 30:5538 (Poster) 　　33. Li Zhang, Meiqi Shi, Cheng Huang, Xiao-Qing Liu, Jian ping Xiong, Gongyan Chen, Wei Liu, Wenchao Liu, Yiping Zhang, Kai Li: A phase II, multi-center, Placebo controlled trial of apatinib in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after 2 previous treatment regimens.Proc Am Soc Clin Oncol 2012;Vol 30:7548 (Poster) 　　34. Tony Mok, Yi-long Wu, Sumitra Thongprasert, Chong-Jen Yu,Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Kate Jin, Matt Truman, Jin Soo Lee: A randomized placebo-controlled phase 3 study of intercalated erlotinib with gemcitabine/platinum in 1st-line advanced non-small-cell lung cancer (NSCLC): FASTACT-2. Proc Am Soc Clin Oncol 2012; Vol 30:7519 (Poster Discussion) 　　35. Caicun Zhou, Yi-long Wu, Xiaoqing Liu, Changli Wang, Gongyan Chen, Jifeng Feng, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chenghong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiyuyi Zhi, Yiping Zhang, Qingyu Xiu: Overall survival (OS) results from OPTIMAL, a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012; Vol 30:7520 (Poster Discussion) 　　36. Liping Zhao, Wanli Liu, Chong Zhao, Xiang Guo, Yan Huang, Fei Xu, Zhihuang Hu, Zhiqiang Wang, Hongyun Zhao,Li Zhang: Pharmacokinetic and pharmacodynamic analysis of fluorouracil in nasopharyngeal cancer patients. Proc Am Soc Clin Oncol 2012;Vol 30:e13021 (Publication) 　　37. Pierre Ferre, Zhimin Shao, Zefei Jiang, Dafang Zhong, Chen Xiaoyan, Jean-Philippe Burillon, Aurélie Petain, Grégoire Zorza, Li Zhang:Is vinorelbine pharmacokinetics modified in Asian patients when compared to Caucasian patients? Proc Am Soc Clin Oncol 2012; Vol 30:e13036 (Publication) 　　38. Shun Lu, Lu Li, Yi Luo, Li Zhang, Zhiwei Chen, Wu Gang, Ping Chen, Cheng Huang, Shuliang Guo Sr., Yiping Zhang, Xiangqun Song, Meijun Lv, Wei Li, Chunhong Hu, Chengping Hu: Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392). Proc Am Soc Clin Oncol 2012; Vol 30:7091(Poster) 　　39. Yan Sun, Yuankai Shi, Li Zhang, Xiaoqing Liu, Caicun Zhou, LI Zhang, Dong Wang, Qiang Li, Shucai Zhang, Shukui Qin, Chunhong Hu, Yiping Zhang, Jianhua Chen, Yong Song, Ji Feng Feng, Ying Cheng, Helong Zhang, Yi Long Wu, Nong Xu, Jianying Zhou: Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. Proc Am Soc Clin Oncol 2012;Vol 30:7559 (Poster) 　　40. T.S.K. Mok, J.S. Lee, L. Zhang, C.-J. Yu, S. Thongprasert, G.E.I. Ladrera, V. Srimuninnimit, M.I. Truman, B. Klughammer, Y.-L. Wu: Biomarker analysis and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in advanced Non-small cell lung cancer (NSCLC).ESMO 2012, (1226O) 　　41. S. Yan, S. Yuankai, Z. Li, L. Xiaoqing, C. Zhou, Z. Li, W. Dong, L. Qiang, Z. Shucai, S. Qin：Final overall survival and update biomarker analysis results from the randomized phase III ICOGEN trial. ESMO 2012, (1269P) 　　42. M. Xie and Z. Li:Preclinical anti-tumor activity of xl880 in nasopharyngeal carcinoma.ESMO 2012, (1027P) 　　43. L.Zhao,W.Liu, X.Guo, C.Zhao, Y.Huang, F.Xuand L. Zhang:Pharmacokinetic and pharmacodynamic analysis of 5-fluorouracil in chinese head and neck cancer (hnc) patients.ESMO 2012, (1057P) 　　44. L. Paz-Ares, V. Hirsh,L. Zhang, F. De Marinis, J.C-H. Yang, H. Wakelee,T. Seto, T. Schmelter, T.J. Ong, T.S.K. Mok, E.F. Smit: Monotherapy administration of sorafenib inpatients with non-small cell lung cancer:phase iii, randomized, double-blind,placebo-controlled MISSION trial.ESMO 2012, (LBA33 PR) 　　45. Y. Wu,Z. Li, C. Zhou, L. Shun, Y. Zhang, M. Hou, W. Liu, J. Wang,G. Chen, Y. Zhou: Multi-center observational study on the diagnosisof non-small cell lung cancer bone metastasisand the efficacyand safety of bisphosphatestreatment (C-TONG 0801).ESMO 2012,(1359P) 　　46. Q. Zhou, C. Zhou, G. Chen, Y. Cheng, C. Huang, L. Zhang, Y-L Wu:A phase II study of sorafenib monotherapy in thepatients with advanced or recurrentnon-small-cell lung cancer after failure ofEGFR-TKI (C-TONG0805).ESMO 2012,(1362TiP) 　　47. Li Zhang, Shun Lu, Ying Cheng, Zhihuang Hu, Zhiwei Chen, Gongyan Chen, Xiaoqing Liu, Jinji Yang, Li Zhang, Jia Chen, Meijuan Huang, Min Tao, Gang Cheng, Cheng Huang, Caicun Zhou, Weimin Zhang, Hong Zhao：Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904). J Clin Oncol 31, 2013 (suppl; abstr 8015) (Poster Discussion) 　　48. Wenhua Liang, Li Zhang： Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Clin Oncol 31, 2013 (suppl; abstr 8089) Poster 　　49. Yan Huang, Li Zhang, Jian-ji Pan, Guoqing Hu, Wu Gang, Jian ping Xiong, Chaosu Hu, Lizhu Lin, Hao Yu, Haoyuan Jiang：A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens. J Clin Oncol 31, 2013 (suppl; abstr 6026) 　　參加臨床研究的情況： 　　作為主要研究者(Principle Investigator and/or Steering Committee member)的研究: 　　1. A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemona?ve patients with stage IIIB-IV non-small cell lung cancer (NSCLC) (NCT00558636). (Principle Investigator and Steering Committee member) 　　2. A multicentre, double-blind randomised, phase III trial to assess the efficacy of Iressa 250mg for Maintenance therapy Following Induction Treatment for Advanced Non Small Cell Lung Cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy(INFORM Study) (NCT00769639)(C-TONG 0804). (Principle Investigator and Steering Committee member) 　　3. A phase II/III randomized, double-blind study of paclitaxel plus carboplatin in combination with vorinostat (MK-0683) or placeboin patients with stage IIIB (with pleural effusion) or stageIV non-small-cell lung cancer (NSCLC)(NCT00473889).(Steering Committee member) 　　4. Efficacy and Safety Study of ZOMETA? in Treatment of High-Level NTX Non Small Cell Lung Cancer With Bone Metastasis (ZEST study) (NCT00762346).(Principle Investigatorand Steering Committee member) 　　5. A Randomized, Placebo-controlled, Double-blind Phase III Study of the Effect of First-line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (FAST-ACT-II) (NCT00883779).(Steering Committee member) 　　6. International randomized study to evaluate the addition of docetaxel to thecombination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF)in the induction treatment of nasopharyngeal carcinoma (NPC) in childrenand adolescents(NCT00565448) (Steering Committee member) 　　7. A Randomised phase II study of oral Vinorelbine in combination with cisplatin versus IV Vinorelbine in combination with cisplatin in unresectable localized or metastatic NSCLC (PM 0259 CA 225 J1).(Principle Investigator) 　　8. Phase II study of combination of Sorafenib with cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who are failure of radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)(NCT00747799).(Principle Investigator) 　　9. Study of Alimta in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have had prior platinum based chemotherapy(NCT00630149).(Principle Investigator) 　　10. To evaluate the efficacy of ZOMETA? in 詳細(xì)介紹